Skip to main content

Table 5 Plasma protein concentrations (fmol/μL) at baseline and at 6 weeks after mirtazapine treatment

From: Alteration of transthyretin and thyroxine-binding globulin in major depressive disorder: multiple reaction monitoring-based proteomic analysis

Protein Responder Nonresponder Responsiveness
Mean ± SD Uni-Pa Mean ± SD Uni-Pa Uni-Pb Multi-Pc
At baseline At 6 week At baseline At 6 week
N 22   21    
AGP1 7872 ± 2719 6967 ± 1610 0.087 7360 ± 3620 6460 ± 1356 0.448 0.280 0.462
HGFA 4.48 ± 1.84 4.21 ± 1.36 0.449 3.79 ± 1.51 4.73 ± 1.83 0.015 0.191 0.270
LBP 31.4 ± 16.2 33.4 ± 12.7 0.219 30.0 ± 10.7 30.8 ± 9.64 0.629 0.585 0.772
Prothrombin 1450 ± 284 1549 ± 383 0.302 1528 ± 412 1486 ± 395 0.657 0.057 0.246
SeP 146 ± 26.2 154 ± 40.4 0.389 157 ± 51.4 158 ± 40.1 0.974 0.397 0.395
TBG 120 ± 28.6 139 ± 38.3 0.007 112 ± 36.2 118 ± 22.5 0.725 0.552 0.511
Transthyretin 6294 ± 1783 6968 ± 2063 0.095 6841 ± 2016 7425 ± 1954 0.209 0.351 0.379
  1. HAM-D Hamilton Depression Rating Scale, SD standard deviation
  2. aP-value from Wilcoxon signed rank test or paired T-test between at baseline and at 6 weeks in each response group
  3. bP-value from Mann–Whitney test or T-test between responders and nonresponders at baseline
  4. cMultivariable P-value from partial Spearman correlation analysis including clinical variables with P < 0.020 (HAM-D score at baseline, and duration of current episode)